A Study to Investigate the Effect of PH-797804 on QTc Interval

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-04-30

Study Completion Date

2013-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate the effect of PH-797804 following dosing of a 24 mg oral tablet on the QTc interval

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate the PF-06700841 Effect on QTc Interval in Healthy Volunteers

NCT03656952

Healthy

COMPLETED PHASE1

A Study To Determine The Effect Of Single-dose PF-04965842 On QTc Interval In Healthy Volunteers Compared With Placebo and Moxifloxacin

NCT03386279

Healthy Volunteers

COMPLETED PHASE1

A Study To Evaluate The Effect Of PF-04447943 On Qtc Interval In Healthy Adult Subjects

NCT02785770

Healthy

COMPLETED PHASE1

A Study of the Effect of RO4917838 on the QTcF Interval in Healthy Volunteers

NCT01613040

Healthy Volunteer

COMPLETED PHASE1

Phase 1 Study to Assess the Effects of EVP-6124 on the QT/QTc Interval in Healthy Subjects

NCT01487135

Healthy Subjects Cardiac Repolarization

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PH-797804

Subjects will receive a single 24 mg dose in the fed state

Group Type EXPERIMENTAL

PH-797804

Intervention Type DRUG

Tablet, 24 mg, single dose

Moxifloxacin

Subjects will receive a single 400 mg dose in the fed state

Group Type EXPERIMENTAL

Moxifloxacin

Intervention Type DRUG

Tablet, 400 mg, single dose

Placebo

Subjects will receive a single placebo dose

Group Type EXPERIMENTAL

Placebo

Intervention Type DRUG

Tablet, PH-797804 matched placebo, single dose

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PH-797804

Tablet, 24 mg, single dose

Intervention Type DRUG

Moxifloxacin

Tablet, 400 mg, single dose

Intervention Type DRUG

Placebo

Tablet, PH-797804 matched placebo, single dose

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy male subjects and/or healthy female subjects of non-child bearing potential between the ages of 18 and 55 years (inclusive). Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurements, 12-lead ECG and clinical laboratory tests.
* Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \> 50 kg (110 lbs).

Exclusion Criteria

* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
* A positive urine drug screen.
* History of regular alcohol consumption exceeding 14 drinks/week for males.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes